DOCSLIB.ORG

Annual Report 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2018 中 國 中 中國中藥控股有限公司 藥 控 股 有 限 公 司 年報 2018 2018 ANNUAL REPORT 2018 年報 China Traditional Chinese Medicine Holdings Co. Limited Co. Holdings Medicine Chinese Traditional China 2018 Annual Report Annual Contents Corporate Information 2 Five Year Financial Summary 3 Chairman’s Statement 5 Management Discussion and Analysis 9 Report of the Directors 30 Corporate Governance Report 52 Biographical Details of Directors and Senior Management 71 Independent Auditor’s Report 77 Consolidated Statement of Profit or Loss and Other Comprehensive Income 83 Consolidated Statement of Financial Position 84 Consolidated Statement of Changes in Equity 86 Consolidated Statement of Cash Flows 87 Notes to the Consolidated Financial Statements 89 Corporate Information BOARD OF DIRECTORS STRATEGIC COMMITTEE Executive Directors Mr. WU Xian (Chairman) Mr. WANG Xiaochun Mr. WU Xian (Chairman) Mr. YANG Wenming Mr. WANG Xiaochun (Managing Director) Mr. YU Tze Shan Hailson Mr. YANG Wenming Mr. QIN Ling Non-executive Directors REGISTERED OFFICE Room 1601, Emperor Group Centre Mr. YANG Shanhua 288 Hennessy Road Ms. LI Ru Wanchai Mr. YANG Binghua Hong Kong Mr. WANG Kan Mr. KUI Kaipin Tel: (852) 2854 3393 Independent Non-executive Directors Fax: (852) 2544 1269 Email: [email protected] Mr. XIE Rong Mr. YU Tze Shan Hailson STOCK CODE Mr. QIN Ling The shares of China Traditional Chinese Medicine Co. Mr. LI Weidong Limited are listed on The Stock Exchange of Hong Kong Limited JOINT COMPANY SECRETARIES Stock code: 00570 Mr. ZHAO Dongji Ms. LEUNG Suet Lun AUDITORS AUDIT COMMITTEE Deloitte Touche Tohmatsu Certified Public Accountants Mr. XIE Rong (Chairman) 35/F., One Pacific Place Mr. YU Tze Shan Hailson 88 Queensway Mr. YANG Shanhua Hong Kong Mr. QIN Ling Mr. LI Weidong SHARE REGISTRAR AND TRANSFER REMUNERATION COMMITTEE OFFICE Computershare Hong Kong Investor Services Limited Mr. QIN Ling (Chairman) Shops 1712-1716 Mr. YANG Shanhua 17th Floor, Hopewell Centre Mr. XIE Rong 183 Queen’s Road East Mr. YU Tze Shan Hailson Wan Chai Mr. LI Weidong Hong Kong NOMINATION COMMITTEE PRINCIPAL BANKERS Mr. WU Xian (Chairman) Bank of China (Hong Kong) Limited Mr. WANG Xiaochun China Merchants Bank Co., Ltd. (Foshan Branch) Mr. YANG Wenming Guangdong Shunde Rural Commercial Bank Co., Ltd. Mr. XIE Rong Industrial and Commercial Bank of China Limited Mr. YU Tze Shan Hailson (Foshan Branch) Mr. QIN Ling Mr. LI Weidong WEBSITE http://www.china-tcm.com.cn 2 China Traditional Chinese Medicine Holdings Co. Limited Five Year Financial Summary (Expressed in RMB) 2014-2018 Compound 2014 2015 2016 2017 2018 Annual RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Growth Rate Results Revenue 2,650,454 3,709,406 6,532,867 8,337,795 11,258,941 43.56% Gross profit 1,643,389 2,200,673 3,787,680 4,651,582 6,193,573 39.33% Profit from operations 551,696 760,978 1,376,783 1,786,453 2,156,025 40.60% Profit before taxation 489,119 689,160 1,303,804 1,567,237 1,856,697 39.58% Profit attributable to the shareholders of the Company 413,090 625,596 966,927 1,170,434 1,439,018 36.62% Profitability Gross profit margin 62.00% 59.33% 57.98% 55.79% 55.01% Operating profit margin 20.82% 20.51% 21.07% 21.43% 19.15% Net profit margin 15.53% 17.36% 16.63% 15.73% 13.92% Earnings per share Basic & Diluted 16.30 cents 16.97 cents 21.73 cents 26.41 cents 29.84 cents 16.32% Financial position Total assets 5,331,852 19,208,676 21,036,784 24,885,307 30,287,390 Total equity attributable to equity shareholders of the Company 3,183,756 11,133,372 11,588,327 12,436,778 15,551,433 Total liabilities 2,074,730 7,068,463 8,280,922 11,070,050 12,776,819 Bank balances and cash 439,416 2,101,856 2,373,356 4,787,781 6,349,714 Debt asset ratio 38.91% 36.80% 39.36% 44.48% 42.19% ANNUAL REPORT 2018 3 Five Year Financial Summary (Expressed in RMB) REVENUE GROSS PROFIT RMB’000 RMB’000 Annual Growth of 2017-2018 Annual Growth of 2017-2018 35.03% 33.15% 11,258,941 6,193,573 8,337,795 4,651,582 6,532,867 3,787,680 3,709,406 2,200,673 2,650,454 1,643,389 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 PROFIT ATTRIBUTABLE TO THE TOTAL ASSETS SHAREHOLDERS OF THE COMPANY RMB’000 RMB’000 Annual Growth of 2017-2018 Annual Growth of 2017-2018 22.95% 21.71% 1,439,018 30,287,390 1,170,434 24,885,307 966,927 21,036,784 19,208,676 625,596 413,090 5,331,852 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 4 China Traditional Chinese Medicine Holdings Co. Limited Chairman’s Statement Chairman’s Statement ANNUAL REPORT 2018 5 Chairman’s Statement Dear shareholders, The year 2018 was an extraordinary one. With strong support from our shareholders, China Traditional Chinese Medicine Holdings Co. Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”) implemented a five-year strategic plan of “building a comprehensive, sustainable and cooperative traditional Chinese medicine (“TCM”) industrial chain, and becoming a leading TCM healthcare complex group in the industry”. A good start was achieved, adding value to the value chain and laying a solid foundation for the Group’s steady development. On behalf of the Board, I would like to express my sincere gratitude to all for your sincere dedication and encouragement. In 2018, the global environment changed in ways that were impossible to predict. A US-China trade war and various regional geopolitical risks created uncertainty in the world economy and led to significant fluctuation across the major stock markets. At the same time, it was a challenging year for the pharmaceutical industry. Despite the growing demand for healthcare in the PRC, cost control became more stringent on medical insurance reimbursements. These changes of national policies had led to dramatically shift on the industry development strategy and the competitive landscape. As benefited from favorable national policies to TCM industry and the trend of TCM modernization, the Group continued to follow its current development strategies while making adjustments to its operational strategies, boosting its production and operational efficiency, and promoting high-quality economic development. All of these measures helped the Company’s results to maintain a continuous rapid growth. During the Reporting Period, the Group’s revenue was RMB11,258,941,000, representing a 35.0% increase from the previous year’s RMB8,337,795,000. The board (the “Board”) of directors (“Directors”) of the Company recognizes the shareholders’ full support by recommending the distribution of a final dividend of HK5.51 cents per share (approximately RMB4.71 cents) for the year ended 31 December 2018, with a payout ratio of 35.0% for the year. Throughout the development history of the Group, it is a process of win-win combination of advantages and mergers and acquisitions. In a number of major mergers, the Board has demonstrated an excellent ability to rapidly understand and respond to the market and execute plans efficiently, which has facilitated the development of the Group’s TCM healthcare complex segment in a rapid manner. Since 2018, the Group has gradually shifted its principal direction from external mergers and acquisitions to strengthening its organic development. In response to internal and external environmental changes, and in order to exploit the resource advantages of the China National Pharmaceutical Group Corporation (“CNPGC”) and strengthen the Group’s four major segments (concentrated TCM granules, TCM decoction pieces, finished drugs and healthcare complex), the Company entered into cooperation with Boston Consulting Group (“BCG”) in October 2018. The measure was taken with the aim of comprehensively rationalizing the Group’s businesses and advantages, identifying the Group’s management conditions and organization structure, devising new management model and a new decision-making mechanism, and implementing strategies for future development. The Company believes that with the help of a leading international consulting company, a strategic analysis and rationalization model, and a strategic goal decomposition calculation method for its strategic management work, its decision-making body will be able to deliver more clear and accurate quantitative results for strategic management. In this way, its business and organization structure will be solidly founded and its direction of development clearly defined, leading to a comprehensively enhanced core competitiveness of the Company in the modern TCM industry. 6 China Traditional Chinese Medicine Holdings Co. Limited Chairman’s Statement STRENGTHENING UPSTREAM AND DOWNSTREAM EXTENSIONS OF THE Industrial Chain, Supporting the Principle “Consolidated HoriZontal AND VERTICAL DEVELOPMENT” In 2018, based on the Board’s development strategy and plans for the Group’s four major business segments, the Group made great efforts to strengthen upstream and downstream extensions of the entire TCM industrial chain under the principle “consolidated horizontal and vertical development”. For upstream business, the Group integrated local Chinese medicinal herbs resources and constructed a standardized TCM industrial chain that extends from seed breeding, plantation and initial processing to logistics and warehousing. This was achieved through developing Chinese medicinal herbs plantation bases, creating a source tracking system for the quality of local Chinese medicinal herbs, and a Chinese medicinal herb dictionary. By taking these actions, the Group established a foundation for implementing quality and cost control on bulk Chinese medicinal herbs. For midstream business, the Company fully seized the window period before the implementation of the market open-up policy, and accelerated the production plan of TCM decoction pieces and concentrated TCM granules across the country.
Load more

Recommended publications
  • Antidepressant-Like Effect and Phytochemical Profile of Supercritical CO2 Extract from Citri Reticulatae Pericarpium
    ORIGINAL ARTICLES Tianjin University of Traditional Chinese Medicine1, Tian Jin; Institute of Medicinal Plant Development2, Chinese Academy of Medical Sciences and Peking Union Medical College, Bei Jing, China Antidepressant-like effect and phytochemical profile of supercritical CO2 extract from Citri reticulatae pericarpium FENGXIA LI1, KANGLI ZHANG1,2, MENG YU2, TONGTONG CHEN1,2, LIYAN MA2, HONGWU ZHANG2, HONGMEI JIA2,*, ZHONGMEI ZOU2,* Received February 18, 2021, accepted March 26. 2021 *Corresponding authors: Zhong Mei Zou, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College. No. 151 Malianwa North Road, Haidian District, Beijing 100193 P. R. China [email protected] HongMei Jia, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College. No. 151 Malianwa North Road, Haidian District, Beijing 100193 P. R. China [email protected] Pharmazie 76: 249-255 (2021) doi: 10.1691/ph.2021.1408 Citri reticulatae pericarpium is a condiment, adding much flavor in Chinese food. Also it can be used to treat depression as a Traditional Chinese Medicine (TCM). The study here aimed to evaluate the antidepressant effect between the supercritical CO2 extract (SC-E) from Citri reticulatae pericarpium and the essential oil extracted by steam distillation (SD-E). And chemical compositions of SC-E were qualitatively analyzed by ultra-perfor- mance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) and gas chro- matography-mass spectrometry (GC-MS). Compared with SD-E, SC-E showed a stronger antidepressant-like effect in FST and TST mice. And it also decreased the content of monoamine oxidase (MAO) in the cerebral cortex of stressed mice.
    [Show full text]
  • View Article
    OPEN ACCESS Freely available online Biology and Medicine Review Article Herbal Prescription for COVID-19 Enqin Zhang* Department of Medicine, UK Academy of Chinese Medicine, United Kindom ABSTRACT The clinical studies from China have proved that the use of herbal medicine has played a significant role in the prevention and treatment of COVID-19. This article aims to introduce the six most effective herbal prescriptions in Traditional Chinese Medicine (TCM) for treating the coronavirus (COVID-19). Each formula has been described in detail including the name, source, indication, ingredients (Chinese Pinyin, English and Latin names), usage and discussion, etc. The first chief formula introduced in this article is the most popular prescription published by The National Health Commission of People’s Republic of China on 3/3 2020 for the treatment and prevention of coronavirus infection and pneumonia; and subsequent formulas are the modified classical herbal prescriptions and my experienced herbal formula I often use in the UK. Keywords: COVID-19; Herbal formulas; Ingredients, Indications; Usage; Discussion INTRODUCTION infected by COVID -19 in the UK. This is why I choose to write this article. The coronavirus (COVID-19) is highly contagious with a characteristic tendency to severely affect the respiratory tract and METHODS the lung in certain individuals .TCM classifies COVID-19 as an epidemic disease termed ‘Wen YI’ and considers both external and Here is detailed information on the anti-coronavirus herbal internal factors contributing to
    [Show full text]
  • Planes, Trains & Automobiles
    PLANES, TRAINS & AUTOMOBILES A Zoom THROUGH CHINA’S INFRASTRUCTURE EXPLOSION Plus 城市漫步珠江三角 洲英文版11月份 E XCLUSIVE interVIEW WITH GuanGZHOU EVERGRANDE'S COACH 国内统一刊号: JOE MONTANA: THE COMEBACK KID COMES CLEAN CN 11-5234/GO China Intercontinental Press THINGS HEAT up at THIS YEAR'S siZZLING sexpo GuanGDONG Dance FESTIVAL takes to THE streets ISLAND in THE sun: THE marVELS of maDAGASCAR November 2013 《城市漫步》珠江三角洲 英文月刊 主管单位: 中华人民共和国国务院新闻办公室 Supervised by the State Council Information Office of the People's Republic of China 主办单位: 五洲传播出版社 地址: 北京市海淀区北三环中路31号生产力大楼B座7层 邮编100088 B-721 Shengchanli Building, No. 31 Beisanhuan Zhonglu, Haidian District, Beijing 100088, PRC http://www.cicc.org.cn 社长 President: 李红杰 Li Hongjie 期刊部负责人 Supervisor of Magazine Department: 邓锦辉 Deng Jinhui Chief Editor Tom Lee Deputy Editor Jane Kent Events and Web Editor Will Wu Staff Writer S. E. Smith Editorial Assistant Van Fan Contributors Marianna Cerini, Eveline Chao, Andrew Chin, Dixon Chow, Aelred Doyle, Stephen George, Stuart Geraghty, Lena Gidwani, Lauren Hogan, Matt Horn, Ned Kelly, Monica Liau, Gary Maidment, Trevor Marshallsea, Patrick Maurer, Legato Midvale, Josh Phillips, Will Phillips, Tongfei Zhang Urbanatomy Media Shanghai (Head office) 上海和舟广告有限公司 上海市澳门路872弄10号 邮政编码: 200050 No.10, Lane 872, Aomen Lu, Shanghai 200050 电话: 021-2213 9018 传真: 021-2213 9010 Guangzhou 上海和舟广告有限公司广州分公司 广州市麓苑路42号大院2号楼610室 邮政编码: 510095 Rm. 610, No. 2 Building, Area 42, Lu Yuan Lu, Guangzhou 510095 电话: 020-8358 6125 传真: 020-8357 3859 - 816 Shenzhen 深圳业务 电话: 0755-8623 3220 传真: 0755-6406
    [Show full text]
  • An Introduction to Chinese Medicine Dermatology
    AN INTRODUCTION TO CHINESE MEDICINE DERMATOLOGY 1 ITCMDA EDITOR’S PROLOGUE 凡大醫治病，必當安神定志，無欲無求， 先發大慈惻隱之心。誓願普救含靈之苦。 Whenever eminent physicians treat an illness…they must first develop a heart full of great compassion and empathy. They must pledge to devote themselves completely to relieving the suffering of all sentient beings.1 - Sun Si Miao, 6th Century Patients with skin diseases suffer not only from physical discomfort but also emotional and social challenges, and high dependence on medications. We are at a moment of great collaboration within integrative medicine. Our hope is that this cooperation will develop greater improvement in the lives of our patients. Chinese medicine dermatology as a specialty and the creation of the ITCMDA In ancient China, during the Confucian times of the late Warring States period (second to third centuries BCE), the practice of medicine was organized into four main specialties - Dietician, Veterinarian, Internal medicine, and Dermatology. Historical records indicate that the system was quite similar to our own modern medical system where a general physician refers patients to the dermatologist when needed, “Whenever those in the state are afflicted with illnesses, with ulcers on the head or with wounds to the body, he [the chief physician] visits them, and then sends them to physicians with an appropriate specialty to cure them.”2 From ancient times until today, Chinese medicine dermatology has been a separate specialty, needing specific training for its successful practice. As Chinese medicine dermatology has such a long history of specialization, it is especially important that there exist a modern organization to aid in the training of students of dermatology, and in assessing the reliability of those that practice Chinese medicine dermatology.
    [Show full text]
  • Detoxification and Inflammation Control—“Hanshi Zufei Decoction”, a Possible Effective Phytotherapy for Mild Cases by Coronavirus Disease 19
    American Journal of Plant Sciences, 2020, 11, 1797-1813 https://www.scirp.org/journal/ajps ISSN Online: 2158-2750 ISSN Print: 2158-2742 Detoxification and Inflammation Control—“Hanshi Zufei Decoction”, a Possible Effective Phytotherapy for Mild Cases by Coronavirus Disease 19 Jingjing Yang, Hualiang Chen* Department of Pharmacy, Shaoxing Seventh People’s Hospital, Shaoxing, Zhejiang Provence, China How to cite this paper: Yang, J.J. and Abstract Chen, H.L. (2020) Detoxification and In- flammation Control—“Hanshi Zufei De- Object: This work explains the theoretical basis of “Hanshi Zufei Decoction” coction”, a Possible Effective Phytotherapy for the treatment of Coronavirus Disease 19 (COVID-19) through Western for Mild Cases by Coronavirus Disease 19. medical theories. Methods: We analyze the guideline of the “Diagnosis and American Journal of Plant Sciences, 11, 1797-1813. Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version https://doi.org/10.4236/ajps.2020.1111129 VII) made by China, “Clinical Management of Severe Acute Respiratory Infec- tion When Novel Coronavirus (2019-nCoV) Infection is Suspected—Interim Received: October 7, 2020 Guidance” made by WHO, “Therapeutic Guidelines: Gastroenteropathy Sec- Accepted: November 27, 2020 Published: November 30, 2020 tion (Version V of Original)” and “Therapeutic Guidelines: Antibiotics Sec- tion (Version XV of Original)” published by Australia, and the origin of clas- Copyright © 2020 by author(s) and sical prescription of “Hanshi Zufei Decoction”: “Shanghan Lun (Treatise on Scientific Research Publishing Inc. This work is licensed under the Creative Febrile Diseases)”, “Jinkui Yaolue (Synopsis of Golden Chamber)” and Commons Attribution-NonCommercial “Wenyi Lun (Treatise on Plague). We search the dictionary of traditional International License (CC BY-NC 4.0).
    [Show full text]
  • Probiotic Potential and Cholesterol-Lowering Capabilities of Bacterial Strains Isolated from Pericarpium Citri Reticulatae ‘Chachiensis’
    microorganisms Article Probiotic Potential and Cholesterol-Lowering Capabilities of Bacterial Strains Isolated from Pericarpium Citri Reticulatae ‘Chachiensis’ Qianxian He, Jingyu Li, Yongkai Ma, Qi Chen and Gu Chen * School of Food Science and Engineering, South China University of Technology, Guangzhou 510640, China; [email protected] (Q.H.); [email protected] (J.L.); [email protected] (Y.M.); [email protected] (Q.C.) * Correspondence: [email protected] Abstract: Pericarpium Citri Reticulatae ‘Chachiensis’ (PCR-Chachiensis), the pericarps of Citri Reticu- latae Blanco cv. Chachiensis, is a food condiment and traditional medicine in southeast and eastern Asia. Its rich and various bacterial community awaits exploration. The present study is the first report on probiotic screening and characterization of bacteria from PCR-Chachiensis. Based on 64 culturable bacterial isolates, 8 strains were screened out to have great survival in the simulated gastrointestinal stressful condition, being nonhemolytic and without biogenic amine formation. They were identified by 16S rRNA gene sequencing as two Bacillus, three Lactobacillus, and three strains from Bacillales. Their probiotic properties, cholesterol-lowering potential and carbohydrate utilization capability were further investigated. Though these eight strains all displayed distinct cholesterol removal potential, Bacillus licheniformis N17-02 showed both remarkable cholesterol removal capability and Citation: He, Q.; Li, J.; Ma, Y.; Chen, presence of bile salt hydrolase gene, as well as possessing most of the desirable probiotic attributes. Q.; Chen, G. Probiotic Potential and Thus, it could be a good probiotic candidate with hypocholesterolemic potential. Bacillus megaterium Cholesterol-Lowering Capabilities of N17-12 displayed the widest carbohydrate utilization profile and the strongest antimicrobial activity.
    [Show full text]
  • (Citrus Reticulata 'Chachi') by Using UPLC-QTOF-MS/MS Based Me
    RSC Advances View Article Online PAPER View Journal | View Issue Chemical and genetic discrimination of commercial Guangchenpi (Citrus reticulata ‘Chachi’) by using Cite this: RSC Adv.,2019,9, 23373 UPLC-QTOF-MS/MS based metabolomics and DNA barcoding approaches† Peng Wang,‡a Jing Zhang,‡a Yating Zhang,a He Su,a Xiaohui Qiu,b Lu Gong,a Juan Huang,a Junqi Bai,a Zhihai Huang*b and Wen Xu *a CRP (Citri Reticulatae Pericarpium), a famous traditional Chinese medicine, has also been extensively used in foods and condiments in dietary practice for centuries. According to the Chinese Pharmacopeia (2015 edition) it contains two subtypes, Guangchenpi (GCP) and Chenpi (CP). GCP exclusively originates from the pericarp of Citrus reticulata ‘Chachi’ cultivar and it's generally believed that GCP has superior qualities compared with the other main cultivars (CP). In the present study, an integrated approach combining LC- QTOF MS-based untargeted metabolomics analysis and DNA barcoding molecular identification was Creative Commons Attribution 3.0 Unported Licence. conducted to study the genetic diversity and chemical differences between GCP and CP. A validated UPLC- QTOF MS metabolomics method was established to identify markers by using PCA and OPLS-DA models. 34 identified metabolites could be used as chemical markers to distinguish effectively between the two subtypes. Among them polymethoxyflavones (PMF) such as hexamethoxyflavone (nobiletin and natsudaidain), pentamethoxyflavone (tangeretin and sinensetin), and tetramethoxyflavonearethemost Received 18th May 2019 influential markers. Support vector machines were employed to classify all the samples and these markers Accepted 2nd July 2019 showed good prediction accuracy (100%). The results of DNA barcoding showed that the secondary DOI: 10.1039/c9ra03740c structure of the ITS2 sequences were significantly different among GCP and other three cultivars.
    [Show full text]
  • Silver Winners 2019
    ARTISAN AWARD WINNERS 2019 ____________________ SILVER "Jams" by Tina Red Grapefruit Marmalade A&E Gourmet Double L for Fish A&E Gourmet Sunshine Marmalade A&E Gourmet The Exotic Purpur A&E Gourmet The Fruity Fragrance of Eden ARTISAN AWARD WINNERS 2019 ____________________ SILVER A&E Gourmet The Man with Flowers A&E Gourmet The Russian Melange Akaka Falls Farm Calamondin Lilikoi Preserve Artisan Kitchen Buck Fizz Preserve Artisan Kitchen Cotswold Honey Lemon Preserve ARTISAN AWARD WINNERS 2019 ____________________ SILVER Artisan Kitchen Lime Lemon Vanilla Preserve Artisan Kitchen London Gin and Orange Mimosa Preserve Artisan Kitchen Negroni Marmalade Artisan Kitchen Seville Cacao Preserve Artisan Kitchen Seville Orange Marmalade ARTISAN AWARD WINNERS 2019 ____________________ SILVER Artisan Kitchen Single Malt Whisky Marmalade Artisan Kitchen Sweet Orange Passion Fruit Preserve Artisan Kitchen Tarocco Blood Orange Preserve Atrium Co Ltd Seville Orange Marmalade Auntie Jane's Four Fruit Marmalade ARTISAN AWARD WINNERS 2019 ____________________ SILVER Awani Bali Sumaga Tangerine Marmalade Bessie's Yorkshire Preserves Citrus Marmalade Blake Hill Preserves Cardamom Infused Meyer Lemon Marmalade Blake Hill Preserves Seville Orange Marmalade Bloom's Amanatsu Marmalade ARTISAN AWARD WINNERS 2019 ____________________ SILVER Bloom's Triple Citrus Marmalade Bonjour! Bonheur Kumquat, Apple and Grapefruit Preserve Borne in Bathurst Festive Marmalade Borne in Bathurst Ruby Grapefruit with Hillyars Yellow Box Honey Bracken Hill Fine Foods Lime Preserve
    [Show full text]
  • Download Download
    Journal of International Society for Food Bioactives Nutraceuticals and Functional Foods Review J. Food Bioact. 2018;4:99–106 Citrus phytochemicals and their potential effects on the prevention and treatment of obesity: review and progress of the past 10 years Shi Fenga,b and Yu Wanga,b* aCitrus Research & Education Center, University of Florida, 700 Experiment Station Rd. Lake Alfred, FL 33850, USA bFood Science and Human Nutrition, University of Florida, 572 Newell Dr. Gainesville, FL 32611, USA *Corresponding author: Yu Wang, Citrus Research & Education Center, University of Florida, 700 Experiment Station Rd. Lake Alfred, FL 33850, USA. Tel: 863-956-8673; Fax: (863)-956-4631; E-mail: [email protected] DOI: 10.31665/JFB.2018.4165 Received: December 10, 2018; Revised received & accepted: December 22, 2018 Citation: Feng, S., and Wang, Y. (2018). Citrus phytochemicals and their potential effects on the prevention and treatment of obesity: review and progress of the past 10 years. J. Food Bioact. 4: 99–106. Abstract Obesity is a chronic life-threatening disease throughout the world. Available anti-obesity drugs may have hazard- ous side effects and no long-term safety assurance is in place for patients. In recent decades, alternative natural therapeutics have been intensively investigated. Among them, phytochemicals from citrus fruits have shown tre- mendous potential to combat obesity through different mechanisms. To date, the most active biological consti- tutes identified in citrus fruits are flavonoids and p-synephrine. These exert anti-obesity effects through multiple mechanisms, including regulating energy intake and expenditure, regulating lipid metabolism and regulating adi- pogenesis. In this mini review, a survey focusing on citrus phytochemicals and their anti-obesity activities is pre- sented, together with an update of findings over the last 10 years, including active components and mechanisms of anti-obesity activities.
    [Show full text]
  • Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia
    Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine on March 3, 2020) Since December 2019, multiple cases of novel coronavirus pneumonia (NCP) have been identified in Wuhan, Hubei. With the spread of the epidemic, such cases have also been found in other parts of China and other countries. As an acute respiratory infectious disease, NCP has been included in Class B infectious diseases prescribed in the Law of the People's Republic of China on Prevention and Treatment of Infectious Diseases, and managed as an infectious disease of Class A. By taking a series of preventive control and medical treatment measures, the rise of the epidemic situation in China has been contained to a certain extent, and the epidemic situation has eased in most provinces, but the incidence abroad is on the rise. With increased understanding of the clinical manifestations and pathology of the disease, and the accumulation of experience in diagnosis and treatment, in order to further strengthen the early diagnosis and early treatment of the disease, improve the cure rate, reduce the mortality rate, avoid nosocomial infection as much as possible and pay attention to the spread caused by the imported cases from overseas, we revised the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6) to Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). I. Etiological Characteristics The novel coronaviruses belong to the β genus. They have envelopes, and the particles are round or oval, often polymorphic, with diameter being 60 to 140 nm.
    [Show full text]
  • 1 PRESS RELEASE World Gourmet Summit 2010 11 – 25 April 2010 the Eu Yan Sang Epicurean Experience
    PRESS RELEASE World Gourmet Summit 2010 11 – 25 April 2010 The Eu Yan Sang Epicurean Experience - An Infusion of Quality Herbs Into Japanese Style Cuisine At the World Gourmet Summit on 21 April 2010 Singapore, 6 April 2010: Singapore’s trusted brand for quality herbs, Eu Yan Sang continues to intrigue gourmands with a special dinner at the World Gourmet Summit on 21 April, at Capella Singapore on Sentosa Island. Featuring a six-course meal by chef-owner Ronnie Chia of Tatsuya Japanese Restaurant, a highly-acclaimed dining establishment in Singapore and Executive Chef Jakob Esko of Capella Singapore, the unique Japanese-style cuisine presented at this dinner will incorporate quality Eu Yan Sang herbs, and is paired with premium vintages from Grand Vin for a truly sensational epicurean experience. In showcasing a creative way of incorporating its premium herbs, Eu Yan Sang aims to indulge diners with a surprising twist, by demonstrating how herbs can be used with everyday cooking. The nourishing benefits of these herbs add to the enjoyment of the meal, as one can relish good food knowing that it will be good for health. “The World Gourmet Summit showcases the finest cuisine around the world and plays an instrumental role in bringing together various cultures through culinary delights. We have worked with various culinary maestros and have successfully demonstrated that Chinese herbs can go very well with different cuisines featuring east-west fusion and seafood menus. This year, we are pairing the herbs with Japanese cuisine and the result is truly sensational”, says Richard Eu, Group CEO of Eu Yan Sang International Ltd.
    [Show full text]
  • Opinion on the Hurdles and Potential Health Benefits in Value-Added Use of Plant Food Processing By-Products As Sources of Pheno
    International Journal of Molecular Sciences Review Opinion on the Hurdles and Potential Health Benefits in Value-Added Use of Plant Food Processing By-Products as Sources of Phenolic Compounds Adriano Costa de Camargo 1,2,3,4,*, Andrés R. Schwember 1, Roberto Parada 1, Sandra Garcia 2 , Mário Roberto Maróstica Júnior 5, Marcelo Franchin 6, Marisa Aparecida Bismara Regitano-d’Arce 3 and Fereidoon Shahidi 4,* 1 Departamento de Ciencias Vegetales, Facultad de Agronomía e Ingeniería Forestal, Pontificia Universidad Católica de Chile, Casilla 306-22, Santiago, Chile; [email protected] (A.R.S.); [email protected] (R.P.) 2 Department of Food Science and Technology, Londrina State University, Londrina 86051-990, Parana State, Brazil; [email protected] 3 Department of Agri-Food Industry, Food & Nutrition, “Luiz de Queiroz” College of Agriculture, University of São Paulo, Piracicaba 13418-900, São Paulo State, Brazil; [email protected] 4 Department of Biochemistry, Memorial University of Newfoundland, St. John’s, NL A1B 3X9, Canada 5 Department of Food and Nutrition, University of Campinas—UNICAMP, Campinas 13083-862, São Paulo State, Brazil; [email protected] 6 Department of Physiological Sciences, Piracicaba Dental School, University of Campinas, Piracicaba 13414-903, São Paulo State, Brazil; [email protected] * Correspondence: [email protected] (A.C.d.C.); [email protected] (F.S.); Tel.: +1-709-864-8552 (F.S.) Received: 1 October 2018; Accepted: 31 October 2018; Published: 6 November 2018 Abstract: Plant foods, their products and processing by-products are well recognized as important sources of phenolic compounds. Recent studies in this field have demonstrated that food processing by-products are often richer sources of bioactive compounds as compared with their original feedstock.
    [Show full text]